Cabaletta Bio, Inc. (CABA) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-03-23

Key Insights

Cabaletta Bio reported its Q4 2025 and full-year 2025 financial results, providing investors with an update on the company's financial performance and operational progress.
The company posted an updated corporate presentation, which likely contains new information on its pipeline, milestones, and strategic initiatives that investors should review.
Investors should monitor any potential changes in Cabaletta's leadership team or key personnel, as management transitions can impact a company's direction and execution.

Want the newest filings?

This analysis covers the filing from 2026-03-23. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-01-12

Cabaletta Bio has initiated a registrational cohort for its rese-cel therapy in dermatomyositis and antisynthetase syndrome, which affects about 70,000 patients in the US, with the potential to submit a Biologics License Application next year.
The company has aligned with the FDA on registrational cohort designs for evaluating rese-cel in systemic lupus erythematosus and lupus nephritis, with updates expected later this year.
Cabaletta is advancing its fully automated, scalable manufacturing for rese-cel using Cellares' Cell Shuttle and Cell Q technology, which could enable rapid global expansion and lower manufacturing costs post-commercialization.

Other reports for Cabaletta Bio, Inc.

Annual Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.